Beam Therapeutics announced positive updates on its BEAM-101 treatment for sickle cell disease (SCD) from the BEACON Phase 1/2 clinical trial, with results presented at the European Hematology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback